Kiadis Pharma Interim Management Statement for the nine months end­ed 30 September 2015

Amsterdam, The Netherlands, November 27, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces its Interim Management Statement for the nine months end­ed 30 September 2015.

Operational review
Kiadis Pharma con­tin­ued to make good progress in devel­op­ing its lead prod­uct ATIR101TM for blood can­cer:
Full enrol­ment of the ongo­ing Phase II clin­i­cal study (CR-AIR-007) with ATIR101TM has been accom­plished. The pri­ma­ry end­point for the last patient in this tri­al will be reached at the end of Q1, 2016 and top-line results will fol­low at the begin­ning of Q2, 2016.
Another study (CR-AIR-008), test­ing repeat dose admin­is­tra­tion of ATIR101TM in par­al­lel with the ongo­ing Phase II tri­al, has been ini­ti­at­ed and has enrolled its first patient.
Establishing a closed man­u­fac­tur­ing process that allows for automa­tion which is advanc­ing accord­ing to plan.

Interim finan­cial results
In the first nine months of 2015, the Company did not gen­er­ate any rev­enues. The net loss for the nine months end­ed 30 September 2015 came at a lev­el of €13.1 mil­lion. Expenses and net results are in line with man­age­ment expec­ta­tions. The Company end­ed the first nine months of 2015 with €31.3 mil­lion in cash and cash equiv­a­lents and an equi­ty posi­tion of €29.1 mil­lion.

Kiadis Pharma list­ed its shares via an IPO on Euronext Amsterdam and Brussels on 2 July 2015. The gross pro­ceeds from the IPO came to a total of €34.7 mil­lion and net pro­ceeds came to a total of €31.2 mil­lion.
The finan­cial infor­ma­tion in this press release has not been audit­ed nor reviewed by the exter­nal audi­tor.

Leave a Reply

Your email address will not be published. Required fields are marked *